| Identification | Back Directory | [Name]
Tivozanib | [CAS]
682745-41-1 | [Synonyms]
Tivozanib hydrochloride
Tivozanib hydrochloride hydrate
1-[2-chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-3-(5-methyl-1,2-oxazol-3-yl)urea
N-[2-Chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)-urea monohydrochloride monohydrate | [Molecular Formula]
C22H22Cl2N4O6 | [MDL Number]
MFCD34184484 | [MOL File]
682745-41-1.mol | [Molecular Weight]
509.34 |
| Chemical Properties | Back Directory | [storage temp. ]
4°C, away from moisture and light | [solubility ]
DMSO : 250 mg/mL (490.83 mM; Need ultrasonic) | [form ]
Solid | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Tivozanib also known as AV-951 is an orally bioavailable potent VEGFR-1, 2 and 3, c-Kit and PDGFR inhibitor with IC50 of 0.21, 0.16, 0.24, 1.63 and 1.72 nM, respectively. | [in vivo]
Tivozanib hydrochloride hydrate (0.04-1 mg/kg, po for 14 days) exhibits antitumor efficacy against breast, colon, hepatic, lung, ovarian, pancreatic, and prostate cancer in athymic mice model[1].
Tivozanib hydrochloride hydrate (0.2-1 mg/kg, po for 21 days) reversibly suppresses vascular permeability and angiogenesis in Calu-6 tumor bearing rats model[1].
Tivozanib hydrochloride hydrate (5 mg/kg, po, single dose) reveals a AUCinf of 44.5 μg·h/mL, Cmax of 2823 ng/mL in athymic mice model[1]. | Animal Model: | Calu-6 tumor bearing athymic mice model[1] | | Dosage: | 0.04-1 mg/kg/day | | Administration: | p.o., for 14-21 days | | Result: |
Inhibited tumor growth, angiogenesis and vascular permeability. |
| [IC 50]
VEGFR-2: 6.5 nM (IC50); VEGFR-3: 15 nM (IC50); VEGFR-1: 30 nM (IC50) | [storage]
4°C, away from moisture and light |
|
|